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Abstract The search to find a more efficient and effective 
way of managing processes, while maintaining the 
integrity of research and manufacturing activities, has led 
pharmaceutical firms, and other actors of the renewed 
pharmaceutical supply chain, to modify their own 
business models. This article aims to emphasize this 
dimension, highlighting, via the observation of a network 
of firms operating at different stages of the 
pharmaceutical supply chain, how business models have 
succeeded in complementing each other and in 
originating a value creation network.  
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1. Introduction 
 
In light of the challenges that the pharmaceutical industry 
is experiencing in mature markets, pharmaceutical and 
biotechnological firms are restructuring their supply 
chains with the aim of reducing costs and maximizing 
productivity.              
 
The consolidation of the industry, resulting from the 
wave of mergers and acquisitions that has interested the 
pharmaceutical and biotechnological world, has led many 
plants to become redundant; many players have 
productive capacities that exceed the actual demand. 
Consequently, several dedicated productive structures – 
for example patent-protected drugs – are losing their 
sheen as branded drugs lose their patent exclusivity and 
face increasing competition from generics.  
 
So far, literature has widely analysed the pharmaceutical 
and biotechnology industry under a number of different 
perspectives, such as the resource-based view [1-2], the 
knowledge-based view [3-5], strategic groups formation 
[6-8], innovation propensity and firm profitability (recent 
studies have empirically tested the influence of a group of 
innovation related variables on company performance, 
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with findings suggesting a positive relationship between 
the two) [9-12], inter-organizational collaboration and 
learning effects [13-16], vertical integration and 
collaborative agreements [3-4], outsourcing [17-19], 
alliance formation [20] and network perspectives [13-15, 
21]. The pharmaceutical industry has, indeed, seen a deep 
transformation in recent years; in terms of the 
geographical concentration of the R&D and commercial 
activities, increased regulatory controls and technological 
complexity and expanding disease targets and cost 
containment policies. The life sciences and biotechnology 
have transformed the prospects and processes of drug 
discovery together with their development, while the rise 
of healthcare and prescription drugs spending has 
induced cost containment policies. Combined, these 
factors have affected the structure of the demand in all 
the major national markets. Stringent requirements for 
the approval of new drugs, together with the orientation 
of research towards increasingly complex pathologies, 
have implied larger, more costly and internationally 
based R&D activities, among others [22].  
 
The rise of the development costs is driving the search to 
find a more efficient and effective way of managing 
processes, while maintaining the integrity of research [23] 
and manufacturing activities. Pharmaceutical firms, and 
other actors of the renewed pharma value chain, have 
replied by modifying their own business models. A 
business model “describes the rationale of how an 
organization creates, delivers and captures value [24]”, or 
in other words draws “stories that explain how 
enterprises work [25]”. Despite the rising importance of 
the business model framework, little attention has been 
devoted to the role played by crises in re-shaping its 
configuration. Furthermore, little attention has been paid 
to the way through which companies may survive the 
crisis by letting their business models complement each 
other in a network,: in fact, once in there, firms will 
eventually be able to compete successfully within the 
changed business ecosystem.  
 
This article aims to emphasize this dimension, 
highlighting how business models have succeeded in 
complementing each other and in originating a value 
creation network. This is done through the observation of 
a network of firms operating at different stages of the 
pharmaceutical value chain. We will thus address the 
following research question: how can business models 
complement each other in a value network and survive 
an industry crisis? 
 
It becomes crucial to consider the effects of exogenous 
shocks within the framework of firms’ business models as, 
even if often unpredictable, crises inevitably play a key 
role in the global business ecosystem. Hence, the purpose 
of this article is to demonstrate that the solution for 
pharmaceutical firms to survive in a new arena of 
competition, will be to let their business models 
complement each other within a network, where the 
missing piece for one firm may be compensated by 
another firm and vice versa. 
 
2. A brand-new chain; innovative business models for 
pharmaceutical firms 
 
At a global level, big pharmaceutical firms execute 
activities that are correlated to different stages of the 
chain, particularly regarding core products, protected by 
intellectual property. The production and distribution of 
their own products is related to the historical vertical 
integration of the pharmaceutical firms that leads them to 
an underutilization of their resources and to an increase 
in their costs. These factors have nurtured the choice, 
from several big firms, to close their plants and outsource 
part of their production to third parties, namely Contract 
Manufacturing Organizations (CMOs). Figure 1 
highlights how, at the different stages, a renewed multi-
player pharmaceutical supply chain has called for 
specialized actors to support integrated firms offering 
specialized services. This drives the general trend of the 
industry to outsource to specialized suppliers activities 
that are complementary to research, like the scouting of 
potential molecules, products for in-licensing strategies 
and activities related to development and trial, through 
the outsourcing of the trials’ coordination to clinical trial 
service firms. Within this new chain, in terms of 
production, the tendency of pharmaceutical firms is to 
outsource to CMOs, combining them with services as 
packaging and formulation. 
 
 
Figure 1. A brand new supply chain. Source: adapted from 
IMAP, 2012 [26] 
 
Among the actors in the pharmaceutical value chain, the 
role of CMOs has been continuously growing. The 
phenomenon of plant–production restructuring and 
outsourcing of excess capacity is mainly evident in 
mature markets, including the US and European 
countries, where a divestiture of productive assets has 
taken place since 2006-2007. 
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From the point of view of big groups, the divestiture of 
productive plants to CMOs is an important effect of the 
reduced production. It represents a strategic action that 
allows firms to withdraw from underused plants, recover 
investments and at the same time achieve an increased 
flexibility in production. A common divestment strategy 
for the big pharmaceutical firms seems to be, in fact, the 
transfer to third parties of production plants and, 
contextually, the signing of medium-long term supply 
contracts for API and pharmaceutical specialties 
produced in the same plants. In this way, these 
companies ensure quality and secured supply while 
offering third parties an initial deposit and then adding 
further contracts. Outsourced production involves both 
active pharmaceutical ingredients, in which several 
suppliers with unique differences, in terms of 
technological platforms and productive capacities, and 
finished goods, are active. Furthermore, to face the needs 
of a highly competitive market, CMOs also aim at 
providing complementary and integrated services, like 
formula development, packaging and distribution. In 
fact, where production is integrated, there is lower risk of 
contamination, and thus a decrease in the cost of finished 
goods. 
 
Relying on CMOs allows traditional pharmaceutical firms 
to foster efficiency on the production side, to reduce time-
to-market and, once demand is decreasing, to flexibly 
adapt to their productive capacity without the need to 
operate in under-efficiency conditions and to face further 
investments in productive assets. On the other hand, for 
the CMOs acquiring such facilities, it becomes possible to 
create investments in line with their strategic needs and, 
while optimizing the usage of internal resources and the 
outsourcing of non-core activities from big-groups, to 
acquire new production-related competences.  
 
The interest towards European sites is increasing both 
from US firms and from Asian acquirers, who are looking 
for assets placed in Western markets in order to enlarge 
their technological basis to ‘scale up’ the drug 
production’s value chain. Competition from Asian firms 
is jeopardizing European firms, both because of the 
increasing quality of the products offered and of the 
lower prices. If CMOs are able to provide a bundle of 
services with high added value, ranging from an 
advanced formula to packaging, while granting low 
contamination, reduced costs and increased efficiency, 
then their relationship with acquirers could become 
stronger in a win-win strategic perspective for both parties, 
with positive returns on the industry and on the firms 
that provide complementary and ancillary products. 
 
The possibility of benefitting from such a specialized 
range of suppliers for different stages of the value chain 
has led pharmaceutical companies to move towards new 
business models. In these models the strategic choices 
related to the organization of the supply chain can be 
framed as the basis of the competitive advantage that 
firms may gain in differentiating their offerings.  
 
In this context of new chain fragmentation, it is possible 
to identify different business models for pharmaceutical 
firms, drawing on different levels of externalization 
extension and on different types of activities that may by 
outsourced or developed through the collaboration of 
external actors. While analysing these collaboration 
patterns in the light of transaction costs theory is not the 
scope of this work, it is important to recall the traditional 
transaction costs economics theory [27-29]. In this theory, 
inter-organizational agreements are intended as 
intermediate forms of transactions between market and 
hierarchy, that may enhance competitive position 
through market power or efficiency [29] and reduce the 
production and transaction costs for the ier involved 
[30]. In light of this, drawing on the idea of “virtual 
manufacturer” [31] firms shows that they operate as 
coordinators standing very close to the “market” edge of 
the continuum between hierarchy and market. Virtual 
manufacturer firms considerably externalize the supply 
chain, from production to distribution, overcoming the 
idea of a “strategic outsourcing”, that aims to restrictions 
of the ties of rigidity or capacity, with a deliberate 
strategy that requires the construction of an integrated 
network of supply partners, acting as a coordinator of the 
entire process. To date, this represents a niche strategy, 
pursued by small specialized firms, that favours a basis of 
flexible costs with minor risks associated with the 
investments and an open access to new technologies and 
competences. Within the continuum, firms may decide to 
operate supply chains that are able to cover both 
production and distribution stages, exploiting a portfolio 
of suppliers to provide innovative healthcare services. In 
order to pursue these strategies, a significant 
restructuring of the chain is required, with a remarkable 
investment in the generation of internal competences and 
of relationships with external actors. To satisfy the 
request for innovative services, these firms need to be 
endowed with a network of reliable and flexible suppliers. 
The differentiation of the offering is made possible thanks 
to the supply of integrated services. Finally, firms may 
decide to exploit the network of partners to enter the 
market as low-cost producers, commercializing products 
at convenient prices. This will require a clear 
comprehension of the operative costs, in a way to allocate 
them precisely between the different products and 
services in their portfolios.  
 
As mentioned, the level of network collaboration needed 
by the virtual manufacturer is intense and requires strong 
coordination competences to manage relationships with a 
large pool of specialized suppliers. A service innovator 
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firm, in order to offer the market a product equipped 
with advanced services, will need organizational and 
relational competences. Turning to external producers or 
distributors seems to be instead very limited for 
traditional models, as these firms have to reach very high 
levels of internal efficiency.  
 
Together with the traditional pharmaceutical value chain, 
it is important to notice there are areas that are tangent to 
chemical-pharmaceutical development, such as 
biotechnologies, that integrate research, enlarging 
commercial areas and increasing the value added to their 
final products. The impact of biotechnologies is 
increasingly rising, and integrates the pharmaceutical 
value chain in its different stages. The chain, hitherto 
intended as a value chain, involves the activities executed 
by pharmaceutical firms to provide value for their clients. 
The pharmaceutical value chain begins with the 
gathering of assets to finance its R&D and ends up with 
the commercialization and sale of the products derived, 
usually with the setting of a premium price. Opposed to 
this value chain is the value chain of the actor paying 
(mainly national healthcare systems or mutual insurances) 
that creates value for its customers while providing them 
with the access to medical care in a regime of quality and 
security. Synergistic to both goals (of pharmaceuticals 
firms and of paying customers) is the complementary 
sector that deals with ensuring the quality and security of 
the process. The analyses of impact on health and on 
environment and the related risks are, in fact, developed 
by a spectrum of heterogeneous actors, ranging from 
firms themselves to societies specialized in the process 
innovation. These entities facilitate and improve control 
in the waste treatment and in the personnel training 
throughout the development and implementation of 
methodologies and technologies. Finally, we add the 
societies specialized in ICT that support crosswise the 
industry along its value chain.  
 
3. How networks reply to new strategic needs  
 
The pharmaceutical industry still plays a primary role in 
the Italian scenario, showing a value of production in 
2013 of €27.6 billion, a 7% increase from 2012, with 
exports leading the entire sector (reaching 71% of the total 
value of production in 2013); however, it lacks the 
investments in innovation needed to drive the 
competitiveness of pharmaceutical firms in the long-run 
(in 2013 R&D expenses accounted for €1.220 billion, a 0.8% 
decrease from 2012) [32]. The recent crisis has in fact 
shifted the competitive arena for pharmaceutical firms. 
Changes in the business models seem to have roots that 
are more profound, attributable to the maturity of the 
market, shrinking productivity, the decrease in research 
outputs and significant changes in the global competitive 
environment. However, for firms within the industry in 
the US and EU regions, the growth gap between the 
domestic markets and the international ones remains 
deep, and forces them to review their strategic paradigms, 
restructuring their value chains, both with a qualitative 
upgrade in the offering and by inserting themselves in 
increasingly global chains.  
 
The industry is far from running out of its 
entrepreneurial cycle, but is aware of the growing 
challenges deriving from the presence in increasingly 
competitive markets. Consequently, it becomes necessary 
to search for solutions that enable the strengthening of 
their business models. Companies are, therefore, seeking 
the collaboration of specialized players. Established and 
emerging life science clusters favour the sharing of know-
how, competences and resources of excellence. These 
interorganizational collaborations can be seen both from a 
resource based and knowledge based perspective. The 
first is in respect to the complementarities in firms’ 
resources, as the firm is a bundle of resources and the 
most common motive for collaborative relations is the 
interdependence in resources. This means that firms form 
alliances with other firms because they are not self-
sufficient, and they cope with the arising uncertainty by 
restructuring their exchange relationships, accessing 
resources held by partners [33-34]. In the latter view, 
collaboration is seen as a means to learn or absorb critical 
skills or capabilities from alliance partners. External 
collaboration is, in this view, complementary to internal 
capabilities in the sense that they facilitate the 
exploitation of existing knowledge [35]. Collaboration 
between firms not only enhances learning about new 
developments, but also strengthens internal competencies 
and thus the locus of innovation is connected to networks 
of learning [13]. 
 
Literature on motives behind cooperation and inter-
organizational agreements leads to the explanation of the 
network genesis processes: industry dynamics and 
market uncertainty drive the search for technological, as 
well as market, opportunities which aﬀect strategic 
choices [36]. The coordination among different subjects 
can enhance the contribution of each actor through its 
own competences and technological assets [13]. Moreover, 
collaboration reduces the exposure of the single actor not 
only to market and technological uncertainty, but also to 
the associated risks and opportunism [37]; risk and 
uncertainty proneness (or aversion) are influenced by the 
network of actors and the environment surrounding the 
firm. Networks have also been identified as loci of 
learning [13], in which routines are specically devoted to 
interorganizational knowledge transfers. According to a 
knowledge-based perspective, networks allow the 
leveraging of network knowledge and the generation of 
competitive advantages based on superior innovation 
[38].  
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The evolution towards strategic networks must be 
guaranteed by an environment that ensures solidity, 
depth and certainty in the relations. Extensive relations 
among partners enhance trust, as shared norms of 
behaviour are established (a dense network activates 
mechanisms of information on opportunistic behaviour 
and threats of sanctions that retain firms from 
malfeasance). Moreover, being actors embedded within 
relational, institutional and cultural contexts, close ties 
increase the likelihood of fine-granted information 
transfers and joint problem-solving arrangements [39]. 
While conducting joint projects, firms combine their 
skills and share their knowledge [40] as common 
partners tend to encourage cooperation, reciprocity and 
sharing [39]. Trust is essential to foster a resource-
sharing mechanism that is less likely to take place in the 
presence of structural holes; the higher the trust among 
actors, the lower the uncertainty about resources 
exchanges. 
 
4. Case study                                                                                                                             
 
We have analysed the case of four Italian firms, located 
in the pharmaceutical district around Latina (Rome) 
and active at different stages of the pharmaceutical 
supply chain. We conducted semi-structured 
interviews [41], mainly related to the nature of their 
aggregation, their future purposes, and how this 
aggregation would have been able to strategically 
revitalize their business models and their area while 
facing the increasingly global competition. We went in 
depth in trying to induce how they believe their new 
competitive model, their network, could step from an 
operational level to embrace more strategic goals, 
while pooling resources and sharing common projects. 
To triangulate our results [42], we then collected 
quantitative data obtained from secondary sources for 
these four companies; in this way we aimed at an in-
depth exploration of the insights that came out from 
our interviews and, thus, from our qualitative method. 
Furthermore, we complemented the findings generated 
from the interviews with the four firms by conducting 
three expert interviews. 
 
Once the data was collected, we coded the interviews and 
categorized concepts that pertained to the same 
phenomenon [43]; then, in order to present in a rigorous 
approach of our coding process, we made use of the Gioia 
methodology, building a data structure that entailed first 
order concepts on one hand, which are “at the level of the 
informant terms and codes [44]” and, on the other, 
second order concepts, that are “at a more abstract level 
[44]”. From the latter, we derived some aggregate 
dimensions to serve as the basis to animate the otherwise 
static concepts that emerged from the interviews, 
eventually developing a grounded theory model. 
We then proceeded by taking a sample of other 
companies (that are not yet part of the network) within 
the pharmaceutical district of Latina, all of which are 
representative of different stages of the supply chain. To 
provide a complete overview of the industry, we covered 
all the related activities, from the production of raw 
materials for the chemical and pharmaceutical industry, 
to the drug discovery and research services, from the 
distribution and sale, to firms that provide consulting 
services related to technological innovation. We included 
both small-medium and large firms in the sample in 
order to grant a heterogeneity of perspectives related to 
the issues investigated. Thus, we were able to highlight 
both the differentials in their business models towards 
their approach to crises and their willingness to take an 
active part in a network as an answer to the crisis that 
they experienced as part of the district. For these firms, 
we conducted semi-standardized interviews structured 
with open-ended questions regarding their business 
models, the future technological trajectories of the specific 
stage of the supply chain, and their perspectives about 
the involvement within a network that could revitalize 
their area and that could give an impulse to the industry 
as a whole. As for the other interviews, we coded them by 
using the Gioia methodology again and then we pooled 
these insights with the ones gained through the 
interviews with the four firms within the network to shed 
brighter light on our grounded theory. Findings of the 
interviews allowed us to trace what follows: the four 
Italian firms located in the pharmaceutical district around 
Latina have decided to establish a network based on the 
“Business network contracts” form (Contratti di rete di 
impresa) that has, since 2009, recognized partnering on 
specific strategic goals and mutual activities with full 
legal effect. The goal of this specific type of contract is to 
increase innovative capacity and competitiveness on the 
market for the firms that decide to partner. It becomes a 
key element to support the construction of strategic 
networks, providing a basis for the formalization of 
relations, rights, duties and governance of the network. 
The existence of a contract also identifies the network as a 
collective but defined subject, with effects on the 
bargaining power and reputation of the partners, 
allowing for the recovery of competitiveness. 
 
The four companies studied include a CMO (Corden 
Pharma), a waste disposal company (Co.Sma.Ri), a 
technological machinery company (CTP Tecnologie di 
Processo) and a training consultancy company (Job 
Consult). Born as a result of entering into a network 
contract between these companies in order to foster the 
competitiveness of firms in the industry and to facilitate 
the economic and technological development, the 
network ‘Pharma Innovazione’ aims to adequately 
respond to the evolution that the market has 
experienced: that is, the need to share resources, 
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tangible and intangible, to put together the knowledge 
and heritage of the key assets to constitute a partnership 
able to meet the growing needs of the demand, the 
saturation of the supply, as well as the cracks that the 
crisis has opened up, by answering the challenges that 
the market presents with one voice. The network, 
through the establishment of highly synergistic actions 
aimed at increasing the competitiveness of the 
participating firms, which also generates a positive 
impact on other companies in the district, aims at 
making the entire area of the Province of Latina, former 
flagship of excellence in the field, the Prime Contract 
Manufacturing Excellence centre in Italy. 
 
According to Pharma Innovazione, transforming the area 
in the Prime Contract Manufacturing Excellence centre in 
Italy will allow firms to create additional value for the 
region of Latium, shifting the focus from the traditional 
customer-supplier relationship to an open system of 
partnerships, a cluster that is able to cope effectively with 
the challenges that the market poses to the industry. 
Collaborating with the aim to develop products and 
services other than those currently in force, in order to 
offer excellence in quality standards, is a goal of vital 
importance for companies who want to ensure a high 
level of competitiveness. 
 
In the face of a national landscape that lacks solid 
investments in specialized knowledge, the network 
Pharma Innovazione, through the collaboration 
agreement, has become the owner of a shared know-how. 
As such, it is a main player in innovative processes and in 
the creation of additional competitive advantage. Within 
the industry, Pharma Innovazione, identified today as a 
collective but defined entity, is a pivotal player in an 
economy where knowledge is a key driver of growth. 
 
The network model allows firms to embrace open 
markets other than the national market, relying on 
partners that are not part of the Italian context, but are 
part of the broader global context; the network Pharma 
Innovazione allows its firms to face the international 
market in the pharmaceutical industry, seizing 
opportunities and overcoming challenges together. Its 
objectives are: (a) sharing of procurement processes and 
creation of a platform to buy certain product categories; 
(b) enhancement, sharing, conversion of the existing 
installation heritage; (c) streamlining of logistics; (d) 
reducing environmental impact and waste management; 
(e) streamlining of energy; (f) development of know-how 
and expertise of the partners and the creation of the Pole 
"PTEC"; (g) launch of industrial research projects; (h) 
development of projects that aim at defining process 
innovations; (i) support change thanks to tools of change 
management.   
 
In order to plan, implement and optimize together the 
activities that the network aims to develop, it is 
fundamental to face three levels of intervention [45].  
 
The first is strategic: it is essential to highlight the 
interactions that the network requires in order to achieve 
its goals, such as the degree, the style and modes of 
collaborations. This forms its construction, with particular 
reference to the definition of supply networks, 
production and distribution. When configuring the 
network, it is also necessary to identify all the actors 
involved in the creation of value for the customer, be they 
other than direct providers, such as providers of 
infrastructures and information. It is in fact important to 
determine the nodes at the basis of the network 'Pharma 
Innovazione’, such as the relative linkages, and who 
among the actors is responsible to achieve them.  
 
The second level is tactical: the focus goes from the 
strategic partnership to the decision of coordination that 
allows deployment in an integrated manner within the 
network flows of materials and information. However, 
considering that it is often complex to align interventions 
related to one or more business functions, the network 
can leverage four drivers of performance that guide the 
operational processes: (a) Plants: pivotal for the 
production management, define which are the places 
where the activities are developed. (b) Inventory: the 
driver that identifies all the raw materials and the 
finished goods within the network; (c) Transportation: 
involves the transfer activities within the network of 
inventory and raw materials (d) Information: is the main 
driver (given its influence on the other three), which 
collects all the data and analyses related to plants, raw 
materials and their modes of transportation.  
 
The last level is the operating one, related to the planning 
of operations and the timely transfer of information, in 
order to monitor the actual status of each organizational 
unit.  
 
 
Figure 2. Pharma Innovazione (P.I.) Network Evolution 
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As noticeable from Figure 2, the network Pharma 
Innovazione, in its lifecycle, is expected to go through 
three stages of evolution (namely defensive, expansive 
and offensive). To date, the network is configured to be in 
a defensive phase: it is in fact mainly focused on creating 
platforms that enable the sharing of logistics, purchasing 
and waste management, in order to boost the efficiency of 
processes and the development not only of the 
pharmaceutical firms that are already part of the network, 
but of all the ones located in the Centre of Italy. In this 
phase, conceiving the network to include other actors, 
whose collaboration would streamline processes once 
granted access to a pool of shared resources that meet the 
needs of ensuring a proper completion of all activities 
foreseen by the chain, would allow firms to climb the 
lifecycle of the network and pass to its next stage. Such 
firms are therefore able to make this transition with 
significant resources, which enable them to realize their 
aspirations and developmental goals. That is why it is 
crucial to think about strengthening the defensive 
position by opening up to incorporate other partners, 
such as those involved in the waste disposal business: to 
free resources and impose security to deal with the 
second phase, that of expansion. In the expansive phase 
other agreements come into play, this time of innovation: 
which is when CRO partners and enterprises that are 
engaged in biotech would allow firms within the network 
respond to the wider and more articulate knowledge that 
the market requires in order to allow, through the use of 
new technologies and the full deployment of skills from 
different parts of the network, the development of more 
effective therapies. These therapies are intended to 
completely meet the needs of patients, and to give that 
boost to the innovation system that, in this area in 
particular, needs to be constantly enhanced. At that point, 
the offensive phase becomes possible for the network. 
This is the stage in which companies come out of the 
corporate boundaries to move to emerging markets and 
to attract the attention of foreign investors, smiting 
competition and continuing to pursue the high standards 
of excellence that have so far allowed the network to 
create and sustain competitive advantage. In this stage, 
contract manufacturing will thus represent a great 
opportunity especially in emerging markets, with Asian 
countries to constitute the main focus for large 
pharmaceutical companies who wish to focus their 
production on outsourcing. 
 
5. Resources and competences to bet on 
 
For firms, there seem to be two main directions in which 
to allocate resources and competences to ensure adequate 
room for growth in the future; namely, first the 
innovation of research and development and secondly, 
innovation in the approach to business (which is focused, 
for example, towards integration schemes and innovative 
distribution, or towards solutions for the integrated 
management of the patient). If innovation in terms of 
research and development is not receiving adequate focus, 
neither is the one related to a different kind of approach 
to business, as the pharmaceutical industry is still 
configured to be a very traditional approach. 
 
The Italian situation is as follows: small businesses are 
very fragmented and not at all focused on the 
development of common projects. Small and medium-
sized enterprises should focus on research abroad and 
scouting, while trying to give life to real market specific 
niches, which could encompass centres of manufacturing 
excellence. The biotech industry has taught, among others, 
how the size is not vital: it is possible for small and 
medium-sized enterprises to play their own winning 
innovation game, generating competitive advantage on a 
global need in niche areas (e.g., rare diseases) and at the 
same time exploiting the commercial geographies. For 
large companies, the key is represented by investments in 
research identified through clear, concrete and achievable 
projects. 
 
The right answer for success in this scenario seems to lie, 
in particular for small firms, in the consortium, in the 
cooperation or even in the network: it is pretty clear to 
firms within the industry how, by themselves, there is no 
more room for growth and development. In addition to 
the product innovations mentioned above, the focus must 
also be maintained on process innovations, in order to 
optimize the production and to provide end users with 
user-friendly interfaces. In this sense, virtual engineering 
projects can also be supported to accelerate the validation 
of new processes and the reconfiguration of existing 
production lines for different products. 
 
Beyond the trajectories of innovative development at a 
product and process level, our interviews have shown 
different sets of resources and expertise needed to 
operate not only in the field - the resources and skills 
"Needed to Play" - but especially those needed to achieve a 
durable competitive advantage for firms - or resources  
 
"Needed to Win". In fact the network as a whole was also 
analysed from the point of view of its endowment, by the 
four current players, of tangible, intangible, human 
resources and distinctive competences. Through this 
analysis, it was possible to understand where the network 
had a solid and durable garrison and had an advantage 
over its competitors. Furthermore, it was possible to 
identify in which areas the garrison is still critical, 
defining a gap with the competences already covered in 
the market by the competitors. With this aim, the 
resources and competences available have been identified 
and classified as belonging to one of the four quadrants in 
the matrix below (Figure 3).  
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Figure 3. A framework for assessing resources and competences. 
Source: Grant R, 2007, [46] 
 
For resources and competences that grant the network a 
superior relative strength (high garrison) and are needed 
to play (even if not to win) in the market, firms are 
endowed with superfluous strengths, which we identified 
to be related to inbound logistics, production, financial 
resources and marketing and sales. When the network 
has a low garrison on resources and competences that are 
merely needed to play the game with its competitors, it 
lacks what we called ‘inconsequential weaknesses’; 
however, once the network lacks the resources and 
competences that are of crucial importance in the market 
and are thus, needed to win (in Figure 3, the bottom right 
box ‘key weaknesses’, which we identified to be, among 
others, outbound logistics and distribution, scouting, 
biotechnology management and product innovation), 
firms will have to look for other partners to join the 
network and make up for the shortage of those specific 
resources and competences. In return, they must provide 
back to these partners ‘key strengths’ (i.e., quality 
management, time-to-market, process innovation) and 
with which firms in the network are already endowed. 
 
It seems clear that the connection among the four 
companies has led to the creation of a portfolio of resources 
and competences needed to win, although the network is 
still recruiting new members to enhance the 
competitiveness of certain R&C that still appear to be weak 
compared to other firms and need to be further developed 
once their strategic importance has been recognized. 
 
On this matter, Pharma Innovazione has been exploring 
the possibility of members acting on two dimensions: the 
first - network width - considering the nature of the agents - 
service agents or production agents, the second - network 
direction - considering the direction of partnership, located 
upstream or downstream of the manufacturing process. 
More specifically, we include in the service agents those 
actors involved in R&D management, quality management, 
waste management, energy management, ICT services 
providers and consumer services providers. Moreover, 
production agents are meant as production plants, logistics, 
distributors, wholesalers and retailers. In addition, we have 
considered the different but closely interdependent supply 
chains that operate in parallel to the pharmaceutical one: 
namely biopharmaceuticals, medical devices and health 
services delivery. The integration of these chains both in 
the case of upstream and downstream players, once 
developed, can lead to a more effective planning process, 
allowing the evaluation and analysis of consumer demand 
for health needs, and to synergies in terms of cost 
reduction or value enhancement for the end user.  
 
The choices regarding the potential partnerships resulting 
from the interplay between the two variables of network 
width and network direction have been synthesized in the 
Pharma Innovazione matrix below (Figure 4). 
 
 
Figure 4. A framework for assessing Pharma Innovazione’s 
potential partnerships 
 
More specifically, we have considered the following areas 
of collaboration: 
1. Upstream Service Agents. We analysed possible 
expansion of the network, observing the inclusion of 
service agents, engaged in the upstream 
manufacturing process. In this sense it is possible to 
consider collaboration with the contract research 
organizations and with actors – that are indeed 
already represented in the network – that provide 
ancillary services, such as quality control, waste 
management and energy efficiency.  
2. Production and Downstream Service Agents. We have 
included in this group collaborations with the 
healthcare providers for the provision of integrated 
services to end users. In addition, collaboration with 
the providers of ancillary services can still happen 
within the downstream structure.  
3. Upstream Production Agents. Shifting the focus to 
manufacturers, and focusing on those that operate 
upstream of the production process, the focus is 
placed immediately on productive activities that 
support experiments and clinical trials. The focus is 
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also on the ramp-up and scale-up of production, 
certainly an area of high-quality for Italian firms as 
compared to competitors in other countries. In 
addition, opportunities arise in the integration with 
parallel chains of medical devices and, more 
importantly, with the biotech industry, certainly 
closer to the pharmaceutical one and with a greater 
growth potential.  
4. Downstream Production Agents. We include in this area 
possible collaboration on the distribution side, in 
order to allow for a reduction of logistics costs and 
value creation for the end customer. In addition, 
collaborating with the biotech and medical device 
industries turns out to be feasible, and desirable, 
even in the early stages of production. 
 
Pharma Innovazione, by analysing and recruiting new 
partners within these areas, will be able to be an agent of 
change, by using the network to incorporate partners that 
can strengthen the supply chain, but also facilitate the 
integration between different sectors. In this way it will be 
possible for firms within the network to pursue new market 
opportunities in related areas. Only by pursuing excellence 
and integration, the network will be able to modulate the 
supply for different types of products and markets, to 
manage sudden changes in demand and operate on the 
moderation of production costs, while maintaining a high 
level of attention on social responsibility and on the 
sustainability of excellent production processes.  
 
6. Conclusions 
  
As for the challenging scenario that surrounds 
pharmaceutical firms, there seems to be something crucial 
that is required to secure the long-term development of 
pharmaceutical companies and their industrial 
environment. This article aims at contributing in this 
direction: when a crisis hits the current business models 
of firms in the global business ecosystem, will not be able 
to generate value in the way they used to, as the 
environment will have dramatically changed. 
  
Management literature has already considered the 
importance of business model innovation, a process that 
establishes firms that should not be undertaken lightly 
[47]: in fact, “one secret to maintain a thriving business is 
recognizing when it needs a fundamental change [47]”. 
However, our contribution will go beyond an innovation 
within a business model: it will entail innovation across 
them, where new ideas can flow as firms merge their 
business models and stand together as one unique player 
that will be able to ride the crisis, and not merely face it. 
 
What managers can consider, thus, is to account for the 
potential shift in the ecosystem while letting their 
business models merge with the business models of other 
firms and give birth to that something crucial, namely a 
network. A network that enables the sharing of activities 
linked to logistics, research and production. In fact, size 
alone is no longer an efficient tool to precisely portray a 
firm’s competitive capacity: what becomes fundamental 
is instead cooperation, cooperation to control all the 
strategic stages of the value chain.  
 
What emerged from the interviews, once rigorously 
coded, is that a network becomes essential to provide a 
sound and sustainable answer to the emerging industry’s 
needs. This as it is able to generate critical mass, allowing 
for the development of know-how whose trace, within a 
model as commercial as the Italian one, is still not visible. 
A network will enable a decrease in costs (as for the 
economies of scale) and will provide firms with the 
strength needed to successfully enter the international 
market. Furthermore, entering by offering excellence can 
be undertaken in two phases: the introduction and launch 
of the product (that requires quality and flexibility in the 
face of the reduced relevance of costs, quality and 
flexibility that are unlikely to be found abroad and that 
represent a strength for the Italian firms), and that of 
production (which also ensures distinctive competences). 
 
According to our findings, here is what pharmaceutical 
firms need to focus on. On a restructuring of their business 
models in a triangle which involves universities 
(laboratories - research centres), government and industry, 
a triangle where each is a vital side, is crucial for the overall 
functioning of the system: where government is no longer 
merely a financing body, but is rather a fundamental 
player to channel firms into trajectories of long-term 
development; where research centres are no longer 
deployed here and there in an area as different entities, 
rather gathered together to focus their efforts and funds to 
provide satisfying answers to the growing demands.   
 
On the exploitation of geographical areas that are 
attractive for the Italian pharmaceutical firms include less 
developed countries where the primary needs deriving 
from basic diseases have not yet been covered, and where 
thus a business model that is different from the Western 
one could be successful. On an ecosystem whose centre 
really stands the patient and the necessity for firms to 
fulfil their role on a 360° basis, by being able to provide 
not just a drug or a product, but a service that constantly 
cares about its patient. On granting a continuous 
investment for the development of new therapeutic 
solutions as, albeit the importance of revolutionizing their 
business models, firms have to recognize that innovative 
products need to be provided also. Biotechnologies 
represent a train that Italy cannot miss. To jump on, and 
exploit its full potential, firms need to coordinate and 
cooperate within a network that is no longer national but 
global.  
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The future of the pharmaceutical industry will be focused 
on two types of firms: blockbuster or innovative. Where 
the former compete on prices, working with immense 
volumes, the latter focus on three principles: speed, quality 
and security. Furthermore, it is on these three principles 
that Italy may offer distinctive services, particularly 
regarding production: in the introduction stages, Italian 
firms may arrive on the market early while offering a 
control that is able to ensure the high quality of products.  
 
It seems clear that the pharmaceutical industry is facing a 
crossroads that is substantially one of mindset: it is necessary 
to stop pursuing the research towards the race for a small 
market share, rather beginning to encourage firms to do 
research on those unmet medical needs and patient 
subcategories. R&D is important in order to be competitive 
in the long run, and develop the necessary added value. 
 
Once pharmaceutical firms have learnt to bet on 
innovation, on the quality delivered and on the R&D, a 
precious heritage opens up for them: a heritage that 
needs to be exploited. That is why, the network needs to 
merge this heritage with the ones of other firms, and give 
rise to an excellence in all the activities of the chain, from 
production, to research, to services.  
 
To date, the scenario surrounding the Italian 
pharmaceutical and biotechnological firms is marked by 
the crisis. The shortage of raising funds (that heavily 
penalizes the sector) is accompanied by a potential 
increase in costs, which makes a radical transformation 
necessary. Our findings agree that, to make this 
transformation possible, firms need to stick together, 
sharing their knowledge and their resources: it is no more 
plausible for firms to spur innovation while remaining 
independent. Furthermore, if innovation is a key to 
remaining competitive, firms can surely build innovation 
with a little help from their network partners. 
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